KORU Medical Q4 revenue rises 23%
Overview
U.S. infusion device maker's Q4 revenue rose 23% yr/yr, full year up 22%
Company posted positive adjusted EBITDA for Q4 and full year
2026 guidance calls for 15-22% revenue growth, positive adjusted EBITDA and cash flow
Outlook
KORU Medical expects 2026 net revenues between $47.5 mln and $50.0 mln, up 15-22%
Company sees 2026 gross margin between 61% and 63%
Company expects positive adjusted EBITDA and positive cash flow for full year 2026
Result Drivers
SCIg DEMAND - Co said domestic core revenue growth was driven by SCIg market growth and new patient starts
INTERNATIONAL EXPANSION - International core revenue growth was driven by increased penetration in established markets and new geographic entries
MATERIAL COSTS AND TARIFFS - Gross margin declined mainly due to higher material costs and tariffs, partially offset by higher average selling prices
Company press release: ID:nBw7bfk1Ba
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Net Income |
| -$500,000 |
|
Q4 Gross Margin |
| 62.6% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for KORU Medical Systems Inc is $7.00, about 55.2% above its March 11 closing price of $4.51
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
